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dose is intrinsic to paediatric practice but is not
supported by guidelines or evidence
Roberta H Richey1*, Utpal U Shah1,2,3, Matthew Peak1,2, Jean V Craig4, James L Ford3, Catrin E Barker1,3,
Anthony J Nunn1,5 and Mark A Turner5,6Abstract
Background: A lack of age-appropriate formulations can make it difficult to administer medicines to children. A
manipulation of the dosage form may be required to achieve the required dose. This study aimed to describe
medicines that are manipulated to achieve the required dose in paediatric practice.
Method: A structured, undisguised observational study and postal survey. The observational study investigated
drug manipulations occurring in clinical practice across three sites. The questionnaire, administered to a sample of
paediatric nurses throughout the UK, surveyed manipulations conducted and nurses’ experiences and views.
Results: The observational study identified 310 manipulations, of which 62% involved tablets, 21% were
intravenous drugs and 10% were sachets. Of the 54 observed manipulations 40 involved tablets with 65% of the
tablets being cut and 30% dispersed to obtain a smaller dose. 188 manipulations were reported by questionnaire
respondents, of these 46% involved tablets, 12% were intravenous drugs, and 12% were nebuliser solutions.
Manipulations were predominantly, but not exclusively, identified in specialist clinical areas with more highly
dependent patients. Questionnaire respondents were concerned about the accuracy of the dose achieved
following manipulations and the lack of practice guidance.
Conclusion: Manipulations to achieve the required dose occur throughout paediatric in-patient settings. The
impact of manipulations on the efficacy of the drugs, the accuracy of the dose and any adverse effects on patients
is not known. There is a need to develop evidence-based guidance for manipulations of medicines in children.
Keywords: Drug manipulation, Survey, Dosage forms, Children's medicinesBackground
A lack of commercially-available, age-appropriate formula-
tions makes it difficult to administer medication to chil-
dren accurately [1-4]. Many medicines given to children
use dosage forms designed for adults [5]. The magnitude
of doses required throughout childhood can vary up to
100-fold [6]. A proportion of the dose in the available
marketed dosage form may be required [7]. Medicines are
thus manipulated by the physical alteration of a dosage
form with the aim of achieving the required (usually
smaller) dose for administration. Examples include* Correspondence: roberta.richey@alderhey.nhs.uk
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reproduction in any medium, provided the orsplitting a tablet and administering a proportion or the
further dilution of an injection when the available concen-
trations do not permit the paediatric dose to be measured
accurately without dilution. Although commonly acknowl-
edged among professionals as a widespread practice,
reports about manipulations with the aim of achieving the
required dose are limited. Manipulations may be time-
consuming, can be inaccurate, and have unknown effects
on the stability and bioavailability of the drug [3,8,9]. This
risks the administration of toxic or sub-therapeutic doses.
Drug manipulations may also increase the risk of errors.
Dose calculation errors are the most common medication
error in neonatal and paediatric practice [10]. Tablet
manipulations have been encouraged (for adults) in some
countries because of economic considerations. There mayLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Manipulation for dose accuracy includes
Tablet • split/broken/cut and a segment given
• crushed and a proportion of the powder given
• dispersed in liquid and a portion of the liquid given
Capsule • opened, dispersed in liquid and a proportion of
the liquid given
• opened and a portion of the powder given
Sachet (powder) • opened, dispersed in liquid and a portion of the
liquid given
• opened and a proportion of the powder given
Oral liquid • diluted and a proportion given (to make the
measurement of a small dose volume easier)
Suppository • cut/split and a segment given
Nebuliser solution • portion given
• diluted and a proportion given
Enema/bladder
irrigation
• proportion of sachet/unit given (the remainder
then discarded)




• patch cut and a portion applied
• portion of patch uncovered and applied
Intravenous
injection
• reconstituted or ready prepared solution, further
diluted to allow a smaller dose to be measured,
• volume of fluid removed from IV container, drug
added (to obtain accurate concentration for infusion)
• drug added to infusion bag, portion with smaller
dose removed and infused
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of the same drug [11,12]. Therefore it may be significantly
cheaper to split tablets than buy the tablet with the opti-
mal dose. A systematic review completed in this area [13]
identified only one study (involving suppositories) that
was not related to splitting tablets. Studies in the system-
atic review included drugs which are used in paediatric
practice, though there were only two papers that included
paediatric participants. Further research and practice guid-
ance is needed.
A key barrier to good practice and research is the lack
of understanding about the scope of manipulations in
paediatric practice. There are few reports about the
settings in which manipulations occur or the types of
manipulations that are performed. Accordingly the aim
of this study was to scope which dosage forms and drugs
are routinely manipulated in paediatric practice. This study
also investigated reasons for undertaking manipulations
and concerns raised by those undertaking manipulations.
Methods
Design
In view of the lack of extant data about the scope of
manipulations in paediatric practice we elected to gather
data in two ways. Firstly we conducted a structured,
undisguised, observational study of drug manipulations
occurring in paediatric practice. Purposive sampling was
used to identify the manipulations occurring in general
and specialised clinical in-patient areas. Subsequently, a
questionnaire was sent to paediatric nurses throughout
the UK. The questionnaire was designed to provide
complementary information about the nature of manip-
ulations in a broader sample and to elicit the views of
paediatric nurses about manipulations.
Table 1 provides the working definitions for dosage
form manipulations that were used for this study.
Observational study
The observational study was conducted at three sites; a
large regional children’s hospital (where all 18 in-patient
wards were included in the observational study); a
regional specialist neonatal unit (54 cots), and a district
general hospital with one paediatric (30 beds, two high
dependency) and one neonatal ward (16 cots). The sites
included 21 different in-patient areas and therefore sim-
ultaneous observations using a simple cross-sectional
design were not feasible. Observations were conducted
in blocks of two weeks. Each block was dedicated to a
ward, or small number of wards at a particular site. During
each two-week block potential manipulations for observa-
tion were identified prospectively via daily prescription
reviews. This was supplemented by the use of alert cards
which nurses were asked to complete where they had
identified a manipulation while administering medicines.Where manipulations were identified, attempts were made
to observe the manipulation occurring in practice. As ma-
nipulations have not been previously observed in practice
a structured observational tool was devised. This tool was
reviewed by clinical and research experts and piloted
within five clinical areas prior to use in the study.
Questionnaire study
The results of the observational study were used in the
design of a questionnaire. This questionnaire was adminis-
tered to paediatric nurses at a variety of geographical loca-
tions in the UK to reduce any potential local bias from
observations undertaken at hospitals within one region.
The questionnaire enabled the collection of additional
data on the nature and type of drug manipulations in
neonatal and paediatric practice and the clinical inpatient
areas in which they occur. Additionally, respondents were
asked to identify the reason that the manipulation oc-
curred and there were questions asking about the avail-
ability of local documentation, any reference sources used
prior to undertaking a manipulation and opportunity was
given to describe any concerns or additional comments.
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and research nurses and a small number of changes made
to ensure clarity for potential questionnaire respondents.
All drug manipulations reported in the questionnaire
responses were reviewed by an experienced paediatric
clinical pharmacist (AJN) to ensure that they met the
criteria to be considered a manipulation to achieve the
required dose.
Paediatric nurse managers across the UK were contacted
and requested to distribute the questionnaires to their
staff. There was no direct communication between the
research team and questionnaire respondents, all ques-
tionnaire responses were anonymous. Managers from 30
hospitals agreed to participate; relative to the size of their
unit, they were sent questionnaires by post, with the
option to request further quantities if required.
The closed questions within the questionnaire were
analysed descriptively. The open questions were analysed
thematically.
Ethical approval
Advice was sought from the local research ethics com-
mittee, which covered all of the hospital sites involved,
who considered that this project did not require ethical
review by a NHS Research Ethics Committee. Prior to
any observation of a drug manipulation verbal consent
from the nurses involved was sought. The protocol spe-
cified that if a potential drug error was witnessed during
the observation then the researchers observing the drug
manipulation would intervene and request that the
calculation or measurement was checked. If the error
was not corrected then the observer would then make
the nurse involved aware of the error prior to any drug
administration to a patient.
Estimating the requirement for manipulation
The observational study was a scoping study which aimed
to examine examples of the type and nature of drug ma-
nipulations across neonatal and paediatric inpatient areas.
In the absence of an evidence-base for this practice, the
sample frame was designed to sample maximum variation
by observing as many different types of drug manipulation
as possible. This led to targeted observations, or purposive
sampling. The resources available could only capture a
diverse sample of manipulations if the research staff were
deployed flexibly. That is, the research team could either
capture ad hoc manipulations they had not yet observed,
or, they could capture a consistent sample of predictable
manipulations. Accordingly the study was not designed to
estimate the frequency of each manipulation. As a supple-
ment to this study, prescription data was collected for five
days for all neonatal and paediatric inpatients in the 21
different inpatient areas used in the observational study.
These data were reviewed by an experienced paediatricpharmacist who used them to provide an estimate of the
requirement for manipulation [14]. This study estimated
that 10% of the evaluated drug administration episodes
would require a manipulation [14]. Given the nature and
wide geographical distribution of the questionnaire study
we were unable to ask respondents to assess the frequency
of the manipulations.Results
Observational study
During the observational study, 310 manipulations were
identified. Researchers did not observe or have to prevent
any drug errors during this study. Many manipulations
were identified in specialist areas or clinical areas with
more highly dependent patients, though manipulations
were identified in all types of wards. Figure 1 details the
clinical areas where manipulations were identified during
the observational study. Of the 310 identified manipula-
tions, 54 (17%) were observed. The patients observed
receiving manipulated drugs encompassed those with a
wide variety of conditions and included an age range from
2 days to 19 years. The main reasons for non-observation
were: the patient not receiving the drug at the prescribed
time (changes in the patient’s condition, patient in
theatre); patient discharged from the ward; changes to the
patient’s prescription (the changes in dose or drug meant
that a manipulation may no longer be required) and diffi-
culties with trying to anticipate when ‘as required’ drugs
would be needed.
Tables 2 and 3 detail the dosage forms and different
drugs involved in the manipulations reported in the
observational study.
Of the 40 tablet manipulations 25 (62.5%) of the tab-
lets were cut, 12 (30%) dispersed, one (2.5%) crushed,
one (2.5%) was broken by hand and there was one
(2.5%) manipulation where the tablet was split in half
first and then dispersed so that a quarter of the dosage
form prior to manipulation could be withdrawn and
administered. In three (11.5%) of the 25 tablet manipula-
tions where the tablet had been split the manipulation
had to be repeated. In two cases the tablet crumbled
while being split, whilst in the third case the tablet split
unevenly. During a further nine (34.6%) of these manip-
ulations there was also visible powder generated when
the tablet was split.
The predominant proportions required for non-
intravenous administration were either a half or a quarter/
three quarters of the dosage form prior to manipulation,
though other proportions were also required (Figure 2).
The intravenous drug manipulations were all reported
in specialist areas; 60% in the specialist neonatal unit,
1.5% in the cardiac unit and 38.5% in paediatric inten-
sive care.
Figure 1 Clinical areas where manipulations were identified during the observational study.
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560 questionnaires were distributed with 153 returned
(27.3% response rate). Questionnaire respondents worked
in a variety of different specialties of neonatal and paediat-
ric practice (Figure 3). 258 potential drug manipulations
were reported by the questionnaire respondents. On
review 70 of these either did not meet the criteria to be
considered manipulations or had not reported sufficient
data, leaving 188 (73%) to be included.
The predominant proportions required for non-intravenous
administration were either a half or a quarter/three quar-
ters of the dosage form prior to manipulation, although
other proportions were required (Figure 2). The intraven-
ous drug manipulations were reported predominantly in
neonatal areas (68.2%), with 18.2% in general paediatrics,
4.5% in each of intensive care, accident and emergency










Tablet 191 (61.6%) 86 (45.7%)
Intravenous
injection
65 (21.0%) 22 (11.7%)
Sachet 30 (9.7%) 2 (1.1%)
Transdermal
patch
10 (3.2%) 20 (10.6%)
Suppository 6 (1.9%) 15 (8.0%)
Capsule 4 (1.3%) 15 (8.0%)
Nebuliser
solution
4 (1.3%) 22 (11.7%)
Enema 0 (0%) 6 (3.2%)
Total 310 (100%) 188 (100%)For 55% of the reported manipulations the sole reason
for the manipulation was that there was ‘no suitable
preparation or strength available’. Further reasons given
for manipulations were, patient preference (reported for
13 (6.9%) manipulations) and usual practice 23 (12.2%).
Thirty five percent of respondents to the questionnaire
reported concerns with the accuracy of the dose achieved
following manipulation. Respondents also noted the im-
portance of good communication between health care
professionals and the need for availability of clear drug
preparation and administration protocols and/or policies
for such scenarios.
Discussion
This study used two complementary approaches to in-
vestigate the scope of manipulations of drugs to achieve
the prescribed dose in neonatal and paediatric practice.the observational study and questionnaire
ons
aire
Number of different drugs
involved – observational study
(percentage)
Number of different drugs
involved – questionnaire
(percentage)
28 (48.3%) 30 (50.8%)
18 (31.0%) 13 (21.3%)
4 (6.9%) 1 (1.6%)
1 (1.7%) 2 (3.3%)
3 (5.2%) 4 (6.6%)
3 (5.2%) 8 (13.1%)
1 (1.7%) 1 (1.6%)
0 (0%) 1 (1.6%)
58 (100%) 60 (100%)
Table 3 Drugs identified as manipulated using British National Formulary for Children (BNFC) classification [19]
BNFC classification Number of manipulations identified – observational
study (percentage)
Number of manipulations identified –
questionnaire (percentage)
Analgesic 92 (29.7%) 33 (17.6%)
Proton pump inhibitor 24 (7.7%) 24 (12.8%)
Antimuscarinic 18 (5.4%) 20 (10.6%)
Antiemetic 17 (5.5%) 5 (2.7%)
Alginate preparation 16 (5.2%) 2 (1.1%)
Antiplatelet 15 (4.8%) 3 (1.6%)
Opioid analgesic 14 (4.5%) 2 (1.1%)
Benzodiazepines 13 (4.2%) 2 (1.1%)
Antiepileptic 12 (3.9%) 6 (3.2%)
Antibiotic 11 (3.5%) 7 (3.7%)
Neuromuscular blocking 11 (3.5%) 0
Steroid 10 (3.2%) 12 (6.4%)
ACE inhibitor 5 (1.6%) 2 (1.1%)
Bronchodilator 5 (1.6%) 23 (12.2%)
Minerals 5 (1.6%) 2 (1.1%)
Thyroid hormone 5 (1.6%) 1 (0.5%)
Vasodilator 5 (1.6%) 1 (0.5%)
Diuretic 4 (1.3%) 0
Drugs affecting the ductus
arteriosus
3 (1.0%) 0
Insulin 3 (1.0%) 0
Laxative 3 (1.0%) 4 (2.1%)
Antipsychotic 2 (0.6%) 1 (0.5%)
Antiviral 2 (0.6%) 1 (0.5%)




H2 antagonist 2 (0.6%) 8 (4.3%)
Inotrope 2 (0.6%) 0
Anticoagulant 1 (0.3%) 2 (1.1%)
Antidepressant 1 (0.3%) 0
Antihypertensive 1 (0.3%) 1 (0.5%)
Antimotility 1 (0.3%) 3 (1.6%)
Pineal hormone 1 (0.3%) 2 (1.1%)
Smooth muscle relaxant 1 (0.3%) 0
Osmotic laxative 0 6 (3.2%)
Immunosuppressant 0 4 (2.1%)
Sedation 0 3 (1.6%)
Calcium channel blocker 0 2 (1.1%)
Cytotoxic 0 2 (1.1%)
Vitamin 0 2 (1.1%)
Beta-blocker 0 1 (0.5%)
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Table 3 Drugs identified as manipulated using British National Formulary for Children (BNFC) classification [19]
(Continued)
Skeletal muscle relaxant 0 1 (0.5%)
Not in BNFC 1 (0.3%) 0
Total 310 (100%) 188 (100%)
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when manipulations are undertaken. Although manipu-
lations were reported more frequently from more spe-
cialist areas, such as neonatal and paediatric intensive
care areas, they occurred in all paediatric in-patient
areas. The manipulations identified involved a wide
range of drugs.
Patient preference was the sole reason for 15% of the
manipulations reported in the questionnaire. This was
also found during the observational study. For example
one child preferred to take half a tablet even though a
liquid formulation was available because taking the
liquid involved a large volume of a liquid whose taste
they did not like.Figure 2 Percentage of the prescribed dose required of the available
and the questionnaire.The predominant concern noted by questionnaire re-
spondents was whether the manipulated medicine would
provide an accurate dose. These concerns have also been
described previously with halving or quartering tablets
[8,15-17]. The need for caution when splitting tablets
with short half-lives or low therapeutic indices [17] has
been highlighted.
A novel finding here is that sizable number of reported
and observed manipulations did not correspond to half
or quarter of the dosage form. The accuracy of dividing
tablets into other fractions is even more unclear that
halves or quarters. The potential lack of accuracy during
manipulations implied by a prescription may mean that
the actual dose delivered to the patient is not known. Itdose for solid dosage forms found in the observational study
Figure 3 Clinical areas questionnaire respondents currently work in.
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dosage form (and strength/concentration) that will be
used to administer the dose required or the potential for
inaccuracy that arises from their prescribed doses.
This study also found that tablets are manipulated by
dispersion in liquid and measurement of a proportion.
Highly variable dosing may occur when insoluble drugs
are dispersed in water [7]. Dispersible tablets can also
yield inconsistent doses when withdrawn from different
depths of the container [18].
Manipulations with the aim of achieving the required
dose are also undertaken with capsules, sachets, supposi-
tories, nebulisers, enemas and transdermal patches. The
manipulation of these other dosage forms has not been
previously investigated. The adverse effects associated
with administering manipulated drugs, of any dosage
form, are unknown. There is a need to conduct research
about high impact manipulations, such as those that
involve an active ingredient with a narrow therapeutic
index or where the physicochemical properties of the
active ingredient may lead to significant changes in
bioavailability following a manipulation.
This study was designed to scope the nature and
occurrence of manipulations and identify priorities for
further research. As such, we used a purposive sampling
approach for maximum variability for the observational
study and a sample of convenience for the questionnaire
study. This precludes quantitative generalisation of our
results. The supplementary quantitative study estimated
that manipulations would be required in approximately
10% of drug administration episodes in the clinical areas
studied in the observational study. Nevertheless, our
methods were sufficiently fine-grained and pragmatic to
yield data that indicate the need for action. The dose of
commonly used medicines was usually calculated from
body weight and dose/kg according to standard practice[19] without rounding to take account of dosage form/
strength. Manipulation of the dosage form was under-
taken with the aim of administering the precise dose. If
other centres are using standard sources, such as BNFC,
they are also likely to be conducting manipulations. The
nature of the issues we have identified would not change
if data were collected from more centres. We note that
our methods gave complementary results. Any further
research on the nature of the problem will need
approaches that provide more than one perspective.
Our results demonstrate that manipulations of dosage
forms are integral to paediatric practice. However, it is
not entirely clear who is responsible for manipulations.
There are two relevant situations, firstly, when the
manipulation is conducted because a suitable dosage
form is not available. This situation may arise because
there is no suitable dosage form on the market, because
a purchasing decision has prevented a suitable dosage
form from being issued from Pharmacy or because a
suitable dosage form is not available on the ward at the
point of need (e.g. at night when Pharmacy staff may not
be available). Secondly, the nurse makes a professional
judgment to meet a patient’s preference when a dosage
form is available. We have developed generic guidelines
about the manipulation of dosage forms in children
(available from the authors). We suggest that paediatric
units should have policies and procedures to cover ma-
nipulation of dosage forms. This should ensure that
there is corporate responsibility for manipulations. For
example, purchasing decisions need to take account of
the manipulations that may result from the choice of
available products. Nurses should have access to the
relevant information and the support from their institu-
tion to make professional judgments about manipula-
tions, many of which are done on off-label or unlicensed
medicines.
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In conclusion manipulations are intrinsic to contemporary
paediatrics. The manipulations conducted in the UK are
not supported by relevant data and raise important issues
of safety, policy and practice. Our data indicates priorities
for policy and research in a neglected but important area
of medicines management.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AN, RR, US, CB, JC, JF MP and MT conceived and designed the study. RR
organised and collected the data. RR, AN and MT prepared the article. All
authors contributed to critical revision of the article and the final draft. All
authors read and approved the final manuscript.
Funding
This paper presents independent research commissioned by the National
Institute for Health Research (NIHR) under its Research for Patient Benefit
(RfPB) Programme (Grant Reference Number PB-PG-0807-13260). The views
expressed are those of the authors and not necessarily those of the NHS, the
NIHR or the Department of Health. The funders were not involved in the
design, collection, analysis and interpretation of the data or in the writing of
the manuscript or the decision to submit for publication.
Author details
1Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP,
UK. 2Cheshire, Merseyside & North Wales Medicines for Children Local
Research Network, Eaton Road, Liverpool L12 2AP, UK. 3School of Pharmacy
& Biomolecular Sciences, Liverpool John Moores University, Byrom Street,
Liverpool L3 3AF, UK. 4Norwich Medical School, Faculty of Medicine and
Health Sciences, University of East Anglia, Norwich NR4 7TJ, UK. 5NIHR
Medicines for Children Research Network Co-ordinating Centre, Institute of
Child Health, University of Liverpool, Liverpool L12 2AP, UK. 6Liverpool
Women’s Hospital NHS Foundation Trust, Crown Street, Liverpool L8 7SS, UK.
Received: 21 November 2012 Accepted: 2 May 2013
Published: 21 May 2013
References
1. Kayitare E, Vervaet C, Ntawukulilyayo JD, Seminega B, Bortel V, Remon JP:
Development of fixed dose combination tablets containing zidovudine
and lamivudine for paediatric applications. Int J Pharm 2009, 370:41–49.
2. Fontan JE, Mille F, Brion F: Drug administration to paediatric patients.
Arch Pediatr 2004, 11:1173–1184.
3. Nunn AJ: Making medicines that children can take. Arch Dis Child 2003,
88:369–371.
4. Nahata MC: Lack of pediatric drug formulations. Pediatrics 1999,
104:607–609.
5. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C,
Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bomati M, Jong G, de Hoog
M, van den Anker J: Survey of unlicensed and off label use in paediatric
wards in European countries. European Network for Drug Investigation
in Children. Br Med J 2000, 320:79–82.
6. Rocchi F, Tomasi P: The development of medicines for children.
Pharmacol Res 2011, 64:169–175.
7. Standing JF, Tuleu C: Paediatric formulations – Getting to the heart of the
problem. Int J Pharm 2005, 300:56–66.
8. Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M: Tablet splitting: a
common yet not so innocent practice. J Adv Nurs 2011, 67:26–32.
9. Skwierczynski C, Conroy S: How long does it take to administer oral
medicines to children? Paediatric Perinatal Drug Therapy 2008, 8:145–149.
10. Conroy S, Sweis D, Planner C, Yeung V, Collier J, Haines L, Wong IC:
Interventions to reduce dosing errors in children: a systematic review of
the literature. Drug Saf 2007, 30:1111–1125.
11. Sayeed VA, Gupta A, Khan MA: Stability of split tablets. Chpt 20. In
Pharmaceutical Stability Testing to Support Global Markets. Edited by Huynh-
Ba K. New York: American Association of Pharmaceutical Scientists; 2010.12. Quinzler R, Gasse C, Scheider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE:
The frequency of inappropriate tablet splitting in primary care. Eur J Clin
Pharmacol 2006, 12:1065–1073.
13. Richey RH, Craig JV, Shah UU, Ford JL, Barker CE, Peak M, Nunn AJ, Turner
MA: The manipulation of drugs to obtain the required dose: systematic
review. J Adv Nurs 2012, 68:2103–2112.
14. Nunn AJ, Richey RH, Shah UU, Barker CE, Craig JV, Peak M, Ford JL, Turner
MA: Estimating the requirement for manipulation of medicines to
provide accurate doses for children. Eur J Hospital Pharm 2013, 20:3–7.
15. Hill SW, Varker AS, Karlage K, Myrdal PB: Analysis of drug content and
weight uniformity for half-tablets of 6 commonly split medications.
J Manag Care Pharm 2009, 15:253–261.
16. van Santen E, Barends DM, Frijlink HW: Breaking of scored tablets: a
review. Eur J Pharm Biopharm 2002, 53:139–145.
17. Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA: Tablet
splitting of a narrow therapeutic index drug: a case with levothyroxine
sodium. AAPS Pharm Sci Tech 2010, 11:1359–1367.
18. Broadhurst EC, Ford JL, Nunn AJ, Rowe PH, Roberts M: Dose uniformity of
samples prepared from dispersible aspirin tablets for paediatric use.
Eur J Hospital Pharm Sci 2008, 14:27–31.
19. Paediatric Formulary Committee (Ed): BNF for Children [2008/2009]. London:
BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2008/2009.
doi:10.1186/1471-2431-13-81
Cite this article as: Richey et al.: Manipulation of drugs to achieve the
required dose is intrinsic to paediatric practice but is not supported by
guidelines or evidence. BMC Pediatrics 2013 13:81.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
